Wordt geladen...
Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
Pompe disease results from acid α-glucosidase (GAA) deficiency, and enzyme replacement therapy (ERT) with recombinant human (rh) GAA has clinical benefits, although its limitations include the short half-life of GAA and the formation of antibody responses. The present study compared the efficacy of...
Bewaard in:
| Gepubliceerd in: | Mol Ther Methods Clin Dev |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Gene & Cell Therapy
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5363303/ https://ncbi.nlm.nih.gov/pubmed/28344998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2016.12.010 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|